Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study

Table 2 Previous therapy, targeted agents, and cytokines (total population, N = 334)

Previous therapy^a	Patients, n (%)	Duration of treatment,^bmedian (range), mo
Sunitinib	260 (78)	9 (0–63)
Sorafenib	68 (20)	6 (0–48)
Pazopanib	12 (4)	3 (1–11)
Bevacizumab^c	41 (12)	6 (0–29)
Cytokines^d	33 (10)	8 (0–113)

^aPatients could have received multiple previous therapies.
^bDuration was calculated for patients with information on duration (sunitinib, n = 251; sorafenib, n = 65; pazopanib, n = 12; bevacizumab, n = 41; cytokines, n = 33).
^cGiven as monotherapy in 14 patients and as part of combination therapy in 27 patients.
^dCombination of cytokines and bevacizumab was included in the bevacizumab category.

ISSN: 1471-2407